期刊文献+

真性红细胞增多症和原发性血小板增多症患者发生再次血栓事件的危险因素分析 被引量:12

Risk factors for recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia
原文传递
导出
摘要 目的分析并探讨真性红细胞增多症(PV)和原发性血小板增多症(ET)患者发生再次血栓事件(再栓)的临床特点及危险因素。方法回顾性分析首都医科大学附属北京安贞医院2001年2月至2016年11月诊治的38例发生再栓事件的ET和PV患者的临床资料,采用Logistic回归分析再栓事件危险因素。结果共计104例首次血栓事件的ET和PV患者中,38例(36.5%)患者发生再栓,年发生率为9.8%/人,ET组、PV组再栓年发生率分别为12.3%/人、5.7%/人。再栓事件共56次,42.1%发生在首次血栓形成后1年内;动脉血栓症占97.4%(以急性冠脉综合征最为多见),静脉血栓症占2.6%。ET组再栓以急性冠脉综合征最多见(18例,64.3%),PV组以脑梗死最常见(7例,70.0%)。2次及以上再栓患者中,PV(9例,90.0%)明显多于ET(7例,25.0%)。再栓组初诊WBC>12.5×10^9/L(52.6%对31.8%,P=0.036)、红细胞比容(Hct)>45%(50.0%对30.0%,P=0.046)、既往血栓史(86.8%对13.6%,P<0.001)、脾肿大(84.2%对33.3%,P<0.001)、治疗未缓解(52.6%对15.2%,P<0.001)、血栓事件分层高危患者占比(94.7%对53.0%,P<0.001)高于单次血栓组;Logistic回归分析显示,既往血栓史(OR=13.697,P=0.025)、脾肿大(OR=13.301,P=0.034)和血栓事件分层高危(OR=44.618,P=0.025)为ET/PV再栓的独立危险因素。结论ET和PV患者有较高的再栓发生率,ET患者再栓发生率高于PV患者,急性冠脉综合征多见;PV多次再栓发生率多于ET,脑梗死较多见。既往血栓史、脾肿大和血栓事件分层高危是再栓的独立危险预测因素。 Objective To analyze the clinical characteristics of recurrent thrombosis in patients with polycythemia vera (PV) and essential thrombocythemia (ET) to probe the risk factors for recurrent thrombosis in patients with ET and PV.Methods The clinical data of 104 ET and PV patients with thrombosis in Beijing Anzhen Hospital from February 2001 to November 2016 were retrospectively analyzed.Thrombosis reoccurred in 38 patients.Statistical analyses were performed by multivariate logistic regression for risk factors of recurrent thrombosis in ET and PV patients.Results Recurrent thrombosis occurred in 36.5% of patients with ET/PV,the total incidence rate in ET and PV patients was 9.8% patient-years,12.3% patient-years and 5.7% patient-years in ET and PV respectively.There were a total of 56 re-thrombotic events,and 42.1% of events occurred within 1 year after the first thrombosis.The arterial re-thrombosis was 97.4%(most of acute coronary syndrome,ACS),and venous events was 2.6%.The most common cases of re-thrombosis were ACS in ET patients (18 cases,64.3%),and cerebral infarction in PV patients (7 cases,70.0%).The number of PV patients with 2 times or more re-thrombotic events was significantly higher than that of ET patients (9 cases,90.0% vs 7 cases,25.0%).The proportion of the patients with WBC>12.5×10^9/L or Hct>45%,and thrombosis history or splenomegaly and high risk thrombotic events were higher than those with a single thrombus (52.6% vs 31.8%;50.0% vs 30.0%;86.8% vs 13.6%;84.2% vs 33.3%;52.6% vs 15.2%;94.7% vs 53.0%;P values were 0.036,0.046,<0.001,<0.001,<0.001 and <0.001,respectively).Logistic regression analysis showed that thrombosis history (OR=13.697,P=0.025),splenomegaly (OR=13.301,P=0.034) and high risk stratification of thrombotic events (OR=44.618,P=0.025) were independent risk factors for recurrent thrombotic events.Conclusions ET and PV patients had a higher risk of re-thrombosis.The incidence of re-thrombosis in ET was higher than in PV,ACS was more common cases of re-thrombotic events;but PV patients were more susceptible to multiple re-thromboses than ET ones,also with more cerebral infarction.Previous thrombus history,splenomegaly and high risk stratification of thrombotic events were independent risk predictors for re-thrombosis of ET and PV patients.
作者 韩雪 白贝贝 王春健 赵森 陈烨 Han Xue;Bai Beibei;Wang Chunjian;Zhao Sen;Chen Ye(Department of Hematology,Beijing Anzhen Hospital,Capital Medical University,Beijing 100029,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2019年第1期17-23,共7页 Chinese Journal of Hematology
基金 首都医科大学附属北京安贞医院院长科技发展基金(2015F01).
关键词 真性红细胞增多症 原发性血小板增多症 再栓事件 危险因素基 Polycythemia vera Essential thrombocythemia Recurrent thrombosis Risk factor
  • 相关文献

二级参考文献72

  • 1Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical Concepts and management recommendations from European LeukemiaNet [J]. J Clin Oncol, 2011, 29 (6):761-770. doi:10.1200/JCO. 2010.31.8436.
  • 2Scott LM, Tong W, Levine RL, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis [J]. N Engl J Med, 2007, 356(5) :459-468. doi: 10.1056/NEJMoa065202.
  • 3Bench A J, White HE, Foroni L, et al. Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations [ J ]. Br J Haematol, 2013, 160(1):25-34. doi: 10.1111/bjh.12075.
  • 4Barbui T, Thiele J, Carobbio A, et al. Masked polycythemia vera diagnosed according to WHO and BCSH classification [J]. Am J Hematol, 2014, 89(2):199-202. doi: 10.1002/ajh.23617.
  • 5Barbui T, Thiele J, Vannucchi AM, et al. Rethinking the diagnos- tic criteria of polycythemia vera [J]. Leukemia, 2014, 28 (6): 1191-1195. doi: 10.1038/leu.2013.380.
  • 6Barosi G, Mesa RA, Thiele J, et al. Proposed criteria for the diagnosis of post- polycythemia vera and post- essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment [J]. Leukemia, 2008, 22(2):437-438. doi:10.1038/sj. leu.2404914.
  • 7Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an intemational study[J]. Leukemia, 2013, 27(9):1874-1881. doi: 10.1038/1eu.2013.163.
  • 8Marchioli R, Finazzi G, Specchia G, et al. Cardiovascular events and intensity of treatment in polycythemia vera [J]. N Engl J Med, 2013, 368( 1 ):22-33. doi: 10.1056/NEJMoa1208500.
  • 9Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera [J]. N Engl J Med, 2004, 350(2):114-124. doi: 10.1056/NEJMoa035572.
  • 10Silver RT, Kiladjian JJ, Hasselbalch HC. Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis [J]. Expert Rev Hematol, 2013, 6 ( 1 ):49-58. doi:10.1586/ehm.12.69.

共引文献122

同被引文献88

引证文献12

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部